¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antigen recognition site"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • carcinoembryonic antigen
    ¾Ï¹è¾ÆÇ׿ø
  • core antigen
    ÇÙ½ÉÇ׿ø
  • cross-reacting antigen
    ±³Â÷¹ÝÀÀÇ׿ø
  • diphasic antigen
    ÀÌ»ó(ì£ßÓ)Ç׿ø
  • early antigen
    ÃʱâÇ׿ø
  • excretory-secretory antigen
    ¹è¼³ºÐºñÇ׿ø
  • egg antigen
    Ãæ¶õÇ׿ø
  • envelope antigen
    ¿ÜÇÇÇ׿ø
  • environmental antigen
    ȯ°æÇ׿ø
  • epithelial membrane antigen
    »óÇǸ·Ç׿ø
  • fimbrial antigen
    °¡´ÂÅÐÇ׿ø
  • flagellar antigen
    Æí¸ðÇ׿ø
  • formalinized antigen
    Æ÷¸£¸»¸°Ã³¸®Ç׿ø
  • functional antigen
    ±â´ÉÇ׿ø
  • granulocyte-erythrocyte antigen
    °ú¸³±¸ÀûÇ÷±¸Ç׿ø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • antigen-recognizing cell
    Ç׿øÀÎÁö¼¼Æ÷
  • avidin-antigen conjugate
    ¾ÆºñµòÇ׿øÁ¢ÇÕü
  • capsid antigen
    ĸ½ÃµåÇ׿ø
  • capsular antigen
    ÇǸ·Ç׿ø
  • circumsporozoite antigen
    Æ÷ÀÚ¼ÒüÇ׿ø
  • colonizing factor antigen
    Áý¶ôÇü¼ºÀÎÀÚÇ׿ø
  • common antigen
    °øÅëÇ׿ø
  • complete antigen
    ¿ÏÀüÇ׿ø
  • conjugated antigen
    °áÇÕÇ׿ø, Á¢ÇÕÇ׿ø
  • core antigen
    ÇÙ½ÉÇ׿ø
  • cross-reacting antigen
    ±³Â÷¹ÝÀÀÇ׿ø
  • diphasic antigen
    ÀÌ»óÇ׿ø
  • early antigen
    ÃʱâÇ׿ø
  • egg antigen
    Ãæ¶õÇ׿ø
  • envelope antigen
    ¿ÜÇÇÇ׿ø
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • H antigen
    H Ç׿ø
  • H antigen
    HÇ׿ø, Æí¸ðÇ׿ø
  • H-Y histocompatibility antigen
    H-Y Á¶Á÷ÀûÇÕ¼º Ç׿ø
  • HBc Ag => hepatitis B core antigen
    B Çü °£¿° c Ç׿ø
  • HBc antigen
    BÇü °£¿°¹ÙÀÌ·¯½º ÇÙ½ÉÇ׿ø
  • HBe Ag => hepatitis B e antigen
    B Çü °£¿° e Ç׿ø
  • HBe antigen
    BÇü °£¿°¹ÙÀÌ·¯½º eÇ׿ø
  • HBs antigen
    BÇü °£¿°¹ÙÀÌ·¯½º Ç¥¸éÇ׿ø
  • HBsAg => hepatitis B surface antigen
    B Çü °£¿° s Ç׿ø
  • HDAg => hepatitis D antigen
    D Çü °£¿°Ç׿ø
  • HLA => human leukocyte antigen
    ÀÎüÁ¶Á÷ÀûÇÕÇ׿ø<ÀÎü¹éÇ÷±¸Ç׿ø>
  • HLA antigen
    HLAÇ׿ø.
  • HLA= human leukocyte antigen ; hist ocompatibility antigens ; tran splan tation antigens
    HLA<Á¶Á÷ÀûÇÕÀ̽Ä>Ç׿ø, ÀιéÇ÷±¸Ç׿ø.
  • HLA= human leukocyte antigen ; histocompatibility antigens ; transplantation anti
    HLA<Á¶Á÷ÀûÇÕÀ̽Ä>Ç׿ø, »ç¶÷¹éÇ÷±¸Ç׿ø.
  • Hepatitis B core antigen(HBc Ag)
    BÇü °£¿°ÇÙ½ÉÇ׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen capture assay
    Ç׿øÆ÷È¹ÃøÁ¤
  • antigen competition
    Ç׿ø°æÀï.
  • antigen detection
    Ç׿ø°ËÃâ
  • antigen diffusion constant
    Ç׿øÈ®»ê»ó¼ö(ù÷ê«üªß¤ßÈâ¦).
  • antigen drift
    Ç׿ø¼Òº¯ÀÌ.
  • antigen excess
    Ç׿ø°ú´Ù(ù÷ê«Î¦Òý).
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen mimicry
    Ç׿øÀ¯»ç¼º.
  • antigen modification
    Ç׿øº¯Çü.
  • antigen presentation
    Ç׿øÁ¦°ø, Ç׿øÀü´Þ, Ç׿øÁ¦½Ã
  • antigen presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • entry site
    ÁøÀÔ(òäìý) ÀÚ¸®
  • E site
    E ÀÚ¸®
  • excluded site binding
    ¹èÁ¦(ÛÉð¶)ÀÚ¸® °áÇÕ(Ì¿ùê)
  • flexible active site
    °¡º¯(ʦܨ) Ȱ¼º(üÀàõ)ÀÚ¸®
  • fluorescent antigen
    Çü±¤ Ç׿ø(û«ÎÃù÷ê«)
  • fragile site
    Ãë¾àºÎÀ§(öªå°Ý»êÈ)
  • half-site editing
    ¹Ý(Úâ)ÀÚ¸® ÆíÁý(øºòþ)
  • H antigen
    H Ç׿ø(ù÷ê«)
  • haptenic antigen
    ÇÕÅÙ Ç׿ø(ù÷ê«)
  • hepatitis B surface antigen
    BÇü(úþ) °£¿°(ÊÜæú) Ç¥¸é Ç׿ø(øúØüù÷ê«)
  • heterogenetic antigen
    ÀÌÁ¾ Ç׿ø(ì¶ðúù÷ê«)
  • heterophile antigen
    ÀÌÈ£¼º Ç׿ø(ì¶û¿àõù÷ê«)
  • hexon antigen
    Çí¼Õ Ç׿ø(ù÷ê«)
  • histocompatibility antigen
    Á¶Á÷ÀûÇÕ¼º Ç׿ø(ðÚòÄîêùêàõù÷ê«)
  • Ia antigen
    Ia Ç׿ø(ù÷ê«)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
SPR sepiapterin reductase; serial probe recognition; specific pathogen free; Society for Pediatric Radio...
SRP short rib-polydactyly [syndrome]; signal recognition particle; Society for Radiological Protection; ...
SRPR signal recognition particle receptor
GnRH Gonadotropin Releasing Hormone  [HP 1898, 2034]
  = LHRH
  = Go...
CMS children's medical services; Christian Medical Society; chronic myelodysplastic syndrome; chromosome...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
ESI Exit-site infection
ESAG expression site-associated gene
HS 2 hypersensitive site 2
GAS IFN-gamma activation site
IGRS Imidazoline-guanidinium-receptive site
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • HL-A type antigen
    ¿¡ÀÌÄ¡¿¤¿¡ÀÌ Ç׿ø
    »ç¶÷ÀÇ ÀûÇ÷±¸ ÀÌ¿ÜÀÇ ¸ðµç ¼¼Æ÷°¡ °¡Áö°í ÀÖ´Â Ç׿ø. »ç¶÷ ¹éÇ÷±¸ Ç׿øÀ̶ó°íµµ ÇÑ´Ù. H´Â »ç¶÷
  • homologous antigen
    »óµ¿ Ç׿ø
  • human histocompatibility antigen
    ÀÎü Á¶Á÷ ÀûÇÕ Ç׿ø
  • human leukocyte antigen-B27
    ÀÎü ¹éÇ÷±¸ Ç×ü-B27
    º¸Åë °­Á÷¼º ôÃß¿° ȯÀÚ¿¡¼­ ³ªÅ¸³ª´Â À¯Àü Ç¥½ÃÀÚ.
  • lymphocyte defined antigen
    ¸²ÇÁ±¸ ±ÔÁ¤ Ç׿ø
  • N-antigen
    N Ç׿ø
  • nuclear antigen
    ÇÙ Ç׿ø
  • pancreatic oncofetal antigen
    ÃéÀåÀÇ Å¾Ƽº ¾Ï Ç׿ø
  • pollen antigen
    ²É°¡·ç Ç׿ø, È­ºÐ Ç׿ø
  • polyvalent antigen
    ´Ù°¡ Ç׿ø
  • self antigen
    ÀÚ±â Ç׿ø
  • somatic antigen
    ±Õü Ç׿ø, ü¼¼Æ÷ Ç׿ø
  • treponema antigen test
    Æ®·¹Æ÷³×¸¶ Ç׿ø ½ÃÇè
  • tumor associated antigen
    ¾Ï °ü·Ã Ç׿ø
    ÀϺÎÀÇ Á¤»ó ¼¼Æ÷¿¡¼­¸¸ ¹ß°ßµÇ¾î ÀÖÀ¸³ª ¾Ï ¼¼Æ÷¿¡¼­µµ ¸¹Àº ¹üÀ§¿¡¼­ ¹ßÇöµÈ Ç׿ø, Á¤»ó ¼¼Æ÷¿¡¼­´Â ¹Ì·®ÀÌ Á¸ÀçÇϳª ¾Ï ¼¼Æ÷¿¡¼­´Â ´Ù·®ÀÌ °ËÃâµÇ´Â Ç׿ø, ±×·¯³ª °áÄÚ ¾Ï ƯÀÌÀûÀ̶ó°í ÇÒ ¼ö ¾ø´Â ¼ºÁúÀÇ Ç׿ø.
  • viral capsid antigen
    ¹ÙÀÌ·¯½º ĸ½Ãµå Ç׿ø, ¹ÙÀÌ·¯½º¼º ĸ½Ãµå Ç׿ø
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
site potential tree A tree that has attained the average maximum height possible given site conditions where it occurs.
(05 Dec 1998)
site preparation Various treatments applied to a harvested area to promote regeneration of the site.
(05 Dec 1998)
site-specific DNA-methyltransferase (adenine-specific) <enzyme> An enzyme responsible for producing a species-characteristic methylation pattern on adenine residues in a specific short base sequence in the host cell DNA. The enzyme catalyses the methylation of DNA adenine in the presence of s-adenosyl-l-methionine to form DNA containing 6-methylaminopurine and s-adenosyl-l-homocysteine.
Registry number: EC 2.1.1.72
(12 Dec 1998)
site-specific DNA methyltransferase (cytosine-specific) <enzyme> An enzyme responsible for producing a species-characteristic methylation pattern on cytosine residues in a specific short base sequence in the host cell's DNA. The enzyme catalyses the methylation of DNA cytosine in the presence of s-adenosyl-l-methionine to form s-adenosyl-l-homocysteine and DNA containing 5-methylcytosine.
Registry number: EC 2.1.1.73
(12 Dec 1998)
site-specific mutagenesis <cell culture, molecular biology> An in vitro technique in which an alteration is made at a specific site in a DNA molecule, which is then reintroduced into a cell. Various techniques are used, for the cell biologist, a very powerful approach to determining which parts of a protein or nucleotide sequence are critical to function.
(18 Nov 1997)
site specific mutation An alteration of the structure of a gene at a specific sequence, usually referring to experimentally produced changes in gene sequence.
(05 Mar 2000)
site-specific recombination <molecular biology> A type of recombination that occurs between two specific short DNA sequences present in the same or in different molecules. An example is the integration and excision of _ prophage.
(18 Nov 1997)
special aquatic site Those sites identified in 40 CRF 230, Subpart E (i.e., sanctuaries and refuges, wetlands, mud flats, vegetated shallows, coral reefs, and riffle and pool complexes). They are geographic areas, large or small, possessing special ecological characteristics of productivity, habitat, wildlife protection, or other important and easily disrupted ecological values. These areas are generally recognised as significantly influencing or positively contributing to the general overall environmental health or vitality of the entire ecosystem of a region. Source: Environmental Protection Agency, 40 CFR
neoplasms by site A collective term for precoordinated organ/neoplasm headings locating neoplasms by organ, as brain neoplasms, duodenal neoplasms, liver neoplasms, etc.
(12 Dec 1998)
switching site The break point in a DNA sequence at which a gene segment unites with another gene segment, as in the production of the immunoglobulins.
(05 Mar 2000)
deoxyribonucleases, type III site-specific <enzyme> Enzyme systems composed of two subunits and requiring ATP and magnesium for endonucleolytic activity; they do not function as atpases. They exist as complexes with modification methylases of similar specificity.
The systems recognise specific short DNA sequences and cleave a short distance, about 24 to 27 bases, away from the recognition sequence to give specific double-stranded fragments with terminal 5'-phosphates. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.5
(12 Dec 1998)
deoxyribonucleases, type II site-specific <enzyme> Enzyme systems containing a single subunit and requiring only magnesium for endonucleolytic activity. The corresponding modification methylases are separate enzymes. The systems recognise specific short DNA sequences and cleave either within, or at a short specific distance from, the recognition sequence to give specific double-stranded fragments with terminal 5'-phosphates. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.4
(12 Dec 1998)
deoxyribonucleases, type I site-specific <enzyme> Enzyme systems containing three different subunits and requiring ATP, s-adenosylmethionine, and magnesium for endonucleolytic activity to give random double-stranded fragments with terminal 5'-phosphates. They function also as DNA-dependent atpases and modification methylases, catalyzing the reactions of EC 2.1.1.72 and EC 2.1.1.73 with similar site-specificity. The systems recognise specific short DNA sequences and cleave at sites remote from the recognition sequence. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.3
(12 Dec 1998)
DNA-(apurinic or apyrimidinic site) lyase <enzyme> Formerly EC 3.1.25.2
Registry number: EC 4.2.99.18
Synonym: endodeoxyribonuclease (apurinic or apyrimidinic), apurinic endonuclease, apurinic DNA endonuclease, purine insertase, endonuclease iv, DNA repair endonuclease, endonuclease vi, endonuclease iv, E coli, bap1, bovine ap endonuclease I, nfo gene product, apci, apcii, apciii, ap lyase, ap endonuclease, hap1 DNA repair enzyme, apurine-apyrimidine endonuclease
(26 Jun 1999)
DNAse i hypersensitivity site <molecular biology> A site on a DNA molecule that is especially prone to being cut apart by the endonuclease enzyme DNase I, which breaks down DNA into smaller fragments by cleaving phosphodiester bonds. These sites tend to be near active genes, which are regularly transcribed.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á